Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-003278
Filing Date
2017-05-02
Accepted
2017-05-02 16:43:01
Documents
41
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nvls-20170331x10q.htm 10-Q 956049
2 EX-31.1 nvls-20170331ex311918161.htm EX-31.1 19835
3 EX-32.1 nvls-20170331ex32141cb8e.htm EX-32.1 7238
  Complete submission text file 0001558370-17-003278.txt   3136903

Data Files

Seq Description Document Type Size
4 EX-101.INS nvls-20170331.xml EX-101.INS 587482
5 EX-101.SCH nvls-20170331.xsd EX-101.SCH 20481
6 EX-101.CAL nvls-20170331_cal.xml EX-101.CAL 26998
7 EX-101.DEF nvls-20170331_def.xml EX-101.DEF 71973
8 EX-101.LAB nvls-20170331_lab.xml EX-101.LAB 218240
9 EX-101.PRE nvls-20170331_pre.xml EX-101.PRE 150441
Mailing Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301
Business Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301 720-945-7700
Nivalis Therapeutics, Inc. (Filer) CIK: 0001626199 (see all company filings)

EIN.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37449 | Film No.: 17805684
SIC: 2834 Pharmaceutical Preparations